Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FNVMX
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,839
Award facts
- Contract value 100% obligated
- $12,839.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded on August 8, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides for the supply of RINVOQ ER 15 mg tablets in a quantity of 30 units. The contract carries a ceiling value of $12,839.40 under firm fixed-price terms with an ultimate completion date of August 11, 2025. This award represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as the primary vehicle for comprehensive pharmaceutical supply to military and federal healthcare systems. The delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting Defense Health Agency and military healthcare programs. The company's extensive federal contract portfolio demonstrates capability in delivering a wide range of pharmaceutical products across multiple therapeutic domains, from specialty medications to generic drugs and medical supplies. RINVOQ ER (upadacitinib extended-release) is a prescription immunosuppressant medication used in the treatment of rheumatoid arthritis and other autoimmune conditions, reflecting the company's role in supplying specialized medications to support military personnel and beneficiary healthcare needs.
Quick answers
Who was awarded contract SPE2DB25FNVMX?
SPE2DB25FNVMX was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 8, 2025.
How much is contract SPE2DB25FNVMX worth?
The government has obligated $12,839 on SPE2DB25FNVMX.
Is contract SPE2DB25FNVMX an order under another contract?
Yes. SPE2DB25FNVMX is a delivery order under SPE2DB25D3201, an indefinite delivery contract.
Was contract SPE2DB25FNVMX competed?
The extent of competition for SPE2DB25FNVMX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award